Diagnostic value of blood thiamine metabolites in Alzheimer's disease examined by

• Published in: Future science OA Vol. 3; no. 2
• Main Authors: Chen, Zhichun, Pan, Xiaoli, Fei, Guoqiang, Pan, Shumei, Bao, Weiqi, Ren, Shuhua, Guan, Yihui, Zhong, Chunjiu
• Format: Journal Article
• Language: English
• Published: Future Science Ltd 01.02.2017; 01.05.2017
• Subjects: Alzheimer's disease; blood biomarker; C-Pittsburgh compound B; diagnosis; PiB negative; PiB positive; positron emission tomography with; thiamine; thiamine diphosphate; thiamine metabolites; γ-value
• ISSN: 2056-5623
• DOI: 10.4155/fsoa-2016-0087

We evaluated the diagnostic value of blood thiamine metabolites for Alzheimer's disease (AD) by using positron emission tomography with C-Pittsburgh compound B ( C-PiB PET) scanning. Thirty-eight clinically diagnosed AD patients were voluntarily recruited. Blood thiamine metabolites were measured by high-performance liquid chromatography. All the patients received C-PiB PET scanning for the measurement of cerebral amyloid deposition. Thiamine diphosphate (TDP) had 66.7% sensitivity and 80.0% specificity for AD diagnosis, while the γ-value representing the best combination of thiamine metabolites and age had 24.2% sensitivity and 100.0% specificity according to the cut-off value of our previous study. Blood TDP but not γ-value exhibited results significant for AD diagnosis. In this study, we investigated the diagnostic value of blood thiamine metabolites for Alzheimer's disease as examined by positron emission tomography with C-Pittsburgh compound B scanning. Our results suggest that the reduction of blood thiamine diphosphate may be a stable biomarker useful for Alzheimer's disease diagnosis.